The EU's open strategic autonomy in the field of pharmaceuticals : overcoming import dependencies for antibiotics through the EU authority HERA / Michael Bayerlein ; Stiftung Wissenschaft und Politik - German Institute for International and Security Affairs
The COVID-19 pandemic and war in Ukraine have highlighted the dependence of the European Union (EU) on individual trading partners. One of the tasks of the European Commission’s new Directorate-General, the Health Emergency Preparedness and Response Authority (HERA), established in 2021, will therefore be to contribute to the EU’s “open strategic autonomy” by identifying and eliminating import dependencies in the field of pharmaceuticals. HERA’s work thus aligns with current EU efforts to reduce concentrated import risks. Here, three aspects of this work are particularly important: the identification of dependencies, the development of strategies to overcome them and the incorporation of these strategies within global health governance..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
[January 2023] |
|---|---|
| Erschienen: |
Berlin: SWP ; January 2023 |
| Reihe: |
SWP comment - 2023, no. 2 (January 2023) |
|---|
| Sprache: |
Englisch |
|---|
| WorkTitle: |
Offene strategische Autonomie der EU im Bereich Arzneimittel [Bayerlein, Michael] |
|---|
| Beteiligte Personen: |
Bayerlein, Michael [VerfasserIn] |
|---|---|
| Körperschaft: |
Stiftung Wissenschaft und Politik [Herausgebendes Organ] |
| Links: |
doi.org [kostenfrei] |
|---|
| Anmerkungen: |
Gesehen am 12.01.2023 "English version of SWP-Aktuell 75/2022" |
|---|
| Umfang: |
1 Online-Ressource (8 Seiten) ; Diagramme |
|---|
| doi: |
10.18449/2023C02 |
|---|---|
| Weitere IDs: |
urn:nbn:de:0168-ssoar-86304-7 10419/268771 |
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1830898299 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1830898299 | ||
| 003 | DE-627 | ||
| 005 | 20231013110814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230112s2023 gw |||||o 00| ||eng c | ||
| 024 | 7 | |a urn:nbn:de:0168-ssoar-86304-7 |2 urn | |
| 024 | 7 | |a 10.18449/2023C02 |2 doi | |
| 024 | 7 | |a 10419/268771 |2 hdl | |
| 035 | |a (DE-627)1830898299 | ||
| 035 | |a (DE-599)KXP1830898299 | ||
| 035 | |a (OCoLC)1369996318 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XA-DE-BE | ||
| 082 | 0 | 4 | |a 658.7 |q DE-101 |
| 082 | 0 | 4 | |a 650 |q DE-101 |
| 084 | |a RA01.01 |2 fivr | ||
| 084 | |a SH02.05 |2 fivs | ||
| 084 | |a SG03.02 |2 fivs | ||
| 100 | 1 | |a Bayerlein, Michael |e verfasserin |0 (DE-588)1213311500 |0 (DE-627)1703850084 |4 aut | |
| 240 | 1 | 0 | |a Offene strategische Autonomie der EU im Bereich Arzneimittel |
| 245 | 1 | 4 | |a The EU's open strategic autonomy in the field of pharmaceuticals |b overcoming import dependencies for antibiotics through the EU authority HERA |c Michael Bayerlein ; Stiftung Wissenschaft und Politik - German Institute for International and Security Affairs |
| 264 | 1 | |a Berlin |b SWP |c [January 2023] | |
| 300 | |a 1 Online-Ressource (8 Seiten) |b Diagramme | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 1 | |a SWP comment |v 2023, no. 2 (January 2023) | |
| 500 | |a Gesehen am 12.01.2023 | ||
| 500 | |a "English version of SWP-Aktuell 75/2022" | ||
| 520 | |a The COVID-19 pandemic and war in Ukraine have highlighted the dependence of the European Union (EU) on individual trading partners. One of the tasks of the European Commission’s new Directorate-General, the Health Emergency Preparedness and Response Authority (HERA), established in 2021, will therefore be to contribute to the EU’s “open strategic autonomy” by identifying and eliminating import dependencies in the field of pharmaceuticals. HERA’s work thus aligns with current EU efforts to reduce concentrated import risks. Here, three aspects of this work are particularly important: the identification of dependencies, the development of strategies to overcome them and the incorporation of these strategies within global health governance. | ||
| 650 | 0 | 7 | |0 (DE-588)4515444-2 |0 (DE-627)248786970 |0 (DE-576)213111268 |a Politische Kooperation |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4020775-4 |0 (DE-627)106316834 |0 (DE-576)208934758 |a Gesundheitswesen |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4136585-9 |0 (DE-627)104180625 |0 (DE-576)209670444 |a Gesundheitsfürsorge |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4003115-9 |0 (DE-627)106390619 |0 (DE-576)208850325 |a Arzneimittel |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4698151-2 |0 (DE-627)353466905 |0 (DE-576)215238613 |a Global Governance |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4026665-5 |0 (DE-627)104313188 |0 (DE-576)208967516 |a Import |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4121927-2 |0 (DE-627)10475625X |0 (DE-576)209547286 |a Wirtschaftliche Abhängigkeit |2 gnd |
| 650 | 0 | 7 | |0 (DE-588)4128891-9 |0 (DE-627)105713937 |0 (DE-576)209605928 |a Importbeschränkung |2 gnd |
| 650 | 4 | |a Health Emergency Preparedness and Response Authority |7 (dpeaa)DE-206 | |
| 650 | 4 | |a HERA |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Biomedical Advanced Research and Development Authority |7 (dpeaa)DE-206 | |
| 650 | 4 | |a BARDA |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Critical Raw Materials Act |7 (dpeaa)DE-206 | |
| 650 | 4 | |a CRMA |7 (dpeaa)DE-206 | |
| 650 | 4 | |a European Raw Materials Alliance |7 (dpeaa)DE-206 | |
| 650 | 4 | |a ERMA |7 (dpeaa)DE-206 | |
| 650 | 4 | |a European Chips Act |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Global Antibiotic Research & Development Partnership |7 (dpeaa)DE-206 | |
| 650 | 4 | |a GARDP |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Innovative Health Initiative |7 (dpeaa)DE-206 | |
| 650 | 4 | |a IHI |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Incubator for Antibacterial Therapies in Europe |7 (dpeaa)DE-206 | |
| 650 | 4 | |a INCATE |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Minerals Security Partnership |7 (dpeaa)DE-206 | |
| 650 | 4 | |a MSP |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Raw Materials Investment Platform |7 (dpeaa)DE-206 | |
| 650 | 4 | |a RMIP |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Covid-19 |7 (dpeaa)DE-206 | |
| 650 | 4 | |a NextGenerationEU |7 (dpeaa)DE-206 | |
| 650 | 4 | |a rescEU |7 (dpeaa)DE-206 | |
| 650 | 4 | |a UN Comtrade |7 (dpeaa)DE-206 | |
| 650 | 4 | |a European Centre for Disease Prevention and Control |7 (dpeaa)DE-206 | |
| 650 | 4 | |a ECDC |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Important Project of Common European Interest |7 (dpeaa)DE-206 | |
| 650 | 4 | |a IPCEI |7 (dpeaa)DE-206 | |
| 650 | 4 | |a pharmaceuticals |7 (dpeaa)DE-206 | |
| 650 | 4 | |a antibiotics |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Active Pharmaceutical Ingredients |7 (dpeaa)DE-206 | |
| 650 | 4 | |a API |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Finished Pharmaceutical Product |7 (dpeaa)DE-206 | |
| 650 | 4 | |a FPP |7 (dpeaa)DE-206 | |
| 650 | 4 | |a supply chains |7 (dpeaa)DE-206 | |
| 650 | 4 | |a global health governance |7 (dpeaa)DE-206 | |
| 650 | 4 | |a Reshoring |7 (dpeaa)DE-206 | |
| 650 | 4 | |a friend-shoring |7 (dpeaa)DE-206 | |
| 710 | 2 | |a Stiftung Wissenschaft und Politik |e Herausgebendes Organ |0 (DE-588)2023076-X |0 (DE-627)102119678 |0 (DE-576)191759279 |4 isb | |
| 775 | 0 | 8 | |i Übersetzung von |a Bayerlein, Michael |t Offene strategische Autonomie der EU im Bereich Arzneimittel |d Berlin : SWP, 2022 |h 1 Online-Ressource (8 Seiten) |w (DE-627)1824453442 |
| 830 | 0 | |a SWP comment |v 2023, no. 2 (January 2023) |9 2023,2 |w (DE-627)1748199498 |w (DE-576)385511523 |w (DE-600)3053616-9 |x 2747-5107 |7 ns | |
| 856 | 4 | 0 | |u https://doi.org/10.18449/2023C02 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://www.swp-berlin.org/publications/products/comments/2023C02_EUAutonomy_Pharmaceuticals.pdf |q application/pdf |x Verlag |z kostenfrei |
| 856 | 4 | 0 | |u https://hdl.handle.net/10419/268771 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:0168-ssoar-86304-7 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:101:1-2023062108472662954217 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://d-nb.info/1293393347/34 |x Langzeitarchivierung Nationalbibliothek |z kostenfrei |
| 912 | |a SSG-OLC-pha | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a ISIL_DE-84 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a ISIL_DE-206 | ||
| 912 | |a GBV_ILN_2403 | ||
| 912 | |a ISIL_DE-LFER | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a ISIL_DE-615 | ||
| 912 | |a ISIL_DE-B1567 | ||
| 936 | f | i | |0 (DE-627)1756131406 |a RA01.01 |b EU/EG sowie Mitgliedsländer |k Europa |k Europäische Organisationen |k EU/EG sowie Mitgliedsländer |2 fivr |
| 936 | f | i | |0 (DE-627)1756136173 |a SH02.05 |b Branchen/Sektorale Entwicklung/Sektorale Wirtschaftspolitik |k Wirtschaft |k Wirtschaftsentwicklung/Wirtschaftspolitik |k Branchen/Sektorale Entwicklung/Sektorale Wirtschaftspolitik |2 fivs |
| 936 | f | i | |0 (DE-627)1756136017 |a SG03.02 |b Gesundheit |k Gesellschaft |k Sozialpolitik/Soziales |k Gesundheit |2 fivs |
| 938 | 1 | 0 | |0 (DE-627)132918269 |0 (DE-588)5098525-5 |a Europäische Union |2 gnd |2 fivt |
| 938 | 1 | 0 | |0 (DE-627)1756187061 |0 (DE-615)6607034 |a Politische Zusammenarbeit |2 fivt |
| 938 | 1 | 0 | |0 (DE-627)1756230994 |0 (DE-615)6608720 |a Gesundheitswesen |2 fivt |
| 938 | 1 | 0 | |0 (DE-627)1756233012 |0 (DE-615)6601174 |a Gesundheitshilfe |2 fivt |
| 938 | 1 | 0 | |0 (DE-627)1756167885 |0 (DE-615)6609043 |a Pharmazeutische Produkte |2 fivt |
| 938 | 1 | 0 | |0 (DE-627)1756148392 |0 (DE-615)6603003 |a Global Health Governance |2 fivt |
| 938 | 1 | 0 | |0 (DE-627)1756236135 |0 (DE-615)6604669 |a Importabhängigkeit |2 fivt |
| 938 | 1 | 0 | |0 (DE-627)175621574X |0 (DE-615)6610050 |a Einfuhrkontrolle |2 fivt |
| 951 | |a BO | ||
| 980 | |2 20 |1 01 |x 0084 |b 4363176377 |y z |z 04-08-23 | ||
| 980 | |2 26 |1 01 |x 0206 |b 4272063197 |c 08 |f --%%-- |d DSP 386 |e --%%-- |j --%%-- |y z1z |z 14-02-23 | ||
| 980 | |2 2403 |1 01 |x DE-LFER |b 4268053638 |c 00 |f --%%-- |d --%%-- |e n |j --%%-- |y l01 |z 07-02-23 | ||
| 980 | |2 2470 |1 01 |x DE-615 |b 4246381748 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |h EDNB-202305 |y l01 |z 12-01-23 | ||
| 980 | |2 2470 |1 02 |x DE-B1567 |b 4247875620 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |y l02 |z 13-01-23 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://doi.org/10.18449/2023C02 | ||
| 981 | |2 2403 |1 01 |x DE-LFER |r https://www.swp-berlin.org/publications/products/comments/2023C02_EUAutonomy_Pharmaceuticals.pdf | ||
| 995 | |2 2470 |1 01 |x DE-615 |a EDNB-202305 | ||
| 998 | |2 2470 |1 01 |x DE-615 |0 2023-01-12 | ||